Literature DB >> 12072527

Identification of the neoplastically transformed cells in Marek's disease herpesvirus-induced lymphomas: recognition by the monoclonal antibody AV37.

Shane C Burgess1, T Fred Davison.   

Abstract

Understanding the interactions between herpesviruses and their host cells and also the interactions between neoplastically transformed cells and the host immune system is fundamental to understanding the mechanisms of herpesvirus oncology. However, this has been difficult as no animal models of herpesvirus-induced oncogenesis in the natural host exist in which neoplastically transformed cells are also definitively identified and may be studied in vivo. Marek's disease (MD) herpesvirus (MDV) of poultry, although a recognized natural oncogenic virus causing T-cell lymphomas, is no exception. In this work, we identify for the first time the neoplastically transformed cells in MD as the CD4(+) major histocompatibility complex (MHC) class I(hi), MHC class II(hi), interleukin-2 receptor alpha-chain-positive, CD28(lo/-), phosphoprotein 38-negative (pp38(-)), glycoprotein B-negative (gB(-)), alphabeta T-cell-receptor-positive (TCR(+)) cells which uniquely overexpress a novel host-encoded extracellular antigen that is also expressed by MDV-transformed cell lines and recognized by the monoclonal antibody (MAb) AV37. Normal uninfected leukocytes and MD lymphoma cells were isolated directly ex vivo and examined by flow cytometry with MAb recognizing AV37, known leukocyte antigens, and MDV antigens pp38 and gB. CD28 mRNA was examined by PCR. Cell cycle distribution and in vitro survival were compared for each lymphoma cell population. We demonstrate for the first time that the antigen recognized by AV37 is expressed at very low levels by small minorities of uninfected leukocytes, whereas particular MD lymphoma cells uniquely express extremely high levels of the AV37 antigen; the AV37(hi) MD lymphoma cells fulfill the accepted criteria for neoplastic transformation in vivo (protection from cell death despite hyperproliferation, presence in all MD lymphomas, and not supportive of MDV production); the lymphoma environment is essential for AV37(+) MD lymphoma cell survival; pp38 is an antigen expressed during MDV-productive infection and is not expressed by neoplastically transformed cells in vivo; AV37(+) MD lymphoma cells have the putative immune evasion mechanism of CD28 down-regulation; AV37(hi) peripheral blood leukocytes appear early after MDV infection in both MD-resistant and -susceptible chickens; and analysis of TCR variable beta chain gene family expression suggests that MD lymphomas have polyclonal origins. Identification of the neoplastically transformed cells in MD facilitates a detailed understanding of MD pathogenesis and also improves the utility of MD as a general model for herpesvirus oncology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12072527      PMCID: PMC136297          DOI: 10.1128/jvi.76.14.7276-7292.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  91 in total

Review 1.  Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics.

Authors:  L J Appleman; D Tzachanis; T Grader-Beck; A A van Puijenbroek; V A Boussiotis
Journal:  J Mol Med (Berl)       Date:  2001       Impact factor: 4.599

2.  Demyelination in allergic and Marek's disease virus induced neuritis. Comparative electron microscopic studies.

Authors:  P Lampert; R Garrett; H Powell
Journal:  Acta Neuropathol       Date:  1977-10-10       Impact factor: 17.088

3.  Avian T cells expressing gamma delta receptors localize in the splenic sinusoids and the intestinal epithelium.

Authors:  R P Bucy; C L Chen; J Cihak; U Lösch; M D Cooper
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

4.  Monomeric homologue of mammalian CD28 is expressed on chicken T cells.

Authors:  J R Young; T F Davison; C A Tregaskes; M C Rennie; O Vainio
Journal:  J Immunol       Date:  1994-04-15       Impact factor: 5.422

5.  [Tumor histogenesis and macrophage content in lymphomas in Marek's disease of chickens].

Authors:  J Beyer; O Werner
Journal:  Arch Exp Veterinarmed       Date:  1990

6.  The role of the macrophages in Marek's disease: in vitro and in vivo studies.

Authors:  K Haffer; M Sevoian; M Wilder
Journal:  Int J Cancer       Date:  1979-05-15       Impact factor: 7.396

7.  Demonstration of a tumor-associated surface antigen in Marek's disease.

Authors:  R L Witter; E A Stephens; J M Sharma; K Nazerian
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

8.  Complete sequence of the chicken glyceraldehyde-3-phosphate dehydrogenase gene.

Authors:  E M Stone; K N Rothblum; M C Alevy; T M Kuo; R J Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

Review 9.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

10.  Serological characterisation of Marek's disease tumour-associated surface antigens on Marek's disease lymphoma cells and on cell lines derived from Marek's disease lymphomas.

Authors:  M Rennie; P C Powell
Journal:  Avian Pathol       Date:  1979-04       Impact factor: 3.378

View more
  13 in total

1.  Marek's disease is a natural model for lymphomas overexpressing Hodgkin's disease antigen (CD30).

Authors:  S C Burgess; J R Young; B J G Baaten; L Hunt; L N J Ross; M S Parcells; P M Kumar; C A Tregaskes; L F Lee; T F Davison
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-08       Impact factor: 11.205

2.  Marek's disease viral interleukin-8 promotes lymphoma formation through targeted recruitment of B cells and CD4+ CD25+ T cells.

Authors:  Annemarie T Engel; Ramesh K Selvaraj; Jeremy P Kamil; Nikolaus Osterrieder; Benedikt B Kaufer
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

3.  Nuclear Factor kappa B is central to Marek's disease herpesvirus induced neoplastic transformation of CD30 expressing lymphocytes in-vivo.

Authors:  Shyamesh Kumar; Dusan Kunec; Joram J Buza; Hsin-I Chiang; Huaijun Zhou; Sugalesini Subramaniam; Ken Pendarvis; Hans H Cheng; Shane C Burgess
Journal:  BMC Syst Biol       Date:  2012-09-14

4.  Clonal structure of rapid-onset MDV-driven CD4+ lymphomas and responding CD8+ T cells.

Authors:  William N Mwangi; Lorraine P Smith; Susan J Baigent; Richard K Beal; Venugopal Nair; Adrian L Smith
Journal:  PLoS Pathog       Date:  2011-05-05       Impact factor: 6.823

5.  Down-regulation of promoter methylation level of CD4 gene after MDV infection in MD-susceptible chicken line.

Authors:  Juan Luo; Ying Yu; Huanmin Zhang; Fei Tian; Shuang Chang; Hans H Cheng; Jiuzhou Song
Journal:  BMC Proc       Date:  2011-06-03

6.  In vitro model for lytic replication, latency, and transformation of an oncogenic alphaherpesvirus.

Authors:  Julia Schermuly; Annachiara Greco; Sonja Härtle; Nikolaus Osterrieder; Benedikt B Kaufer; Bernd Kaspers
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-26       Impact factor: 11.205

Review 7.  Virus and host genomic, molecular, and cellular interactions during Marek's disease pathogenesis and oncogenesis.

Authors:  M C McPherson; M E Delany
Journal:  Poult Sci       Date:  2016-01-11       Impact factor: 3.352

8.  Genotype-dependent tumor regression in Marek's disease mediated at the level of tumor immunity.

Authors:  Shyamesh Kumar; Joram J Buza; Shane C Burgess
Journal:  Cancer Microenviron       Date:  2009-03-18

9.  Histone methylation analysis and pathway predictions in chickens after MDV infection.

Authors:  Juan Luo; Apratim Mitra; Fei Tian; Shuang Chang; Huanmin Zhang; Kairong Cui; Ying Yu; Keji Zhao; Jiuzhou Song
Journal:  PLoS One       Date:  2012-07-26       Impact factor: 3.240

10.  Prediction of peptides observable by mass spectrometry applied at the experimental set level.

Authors:  William S Sanders; Susan M Bridges; Fiona M McCarthy; Bindu Nanduri; Shane C Burgess
Journal:  BMC Bioinformatics       Date:  2007-11-01       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.